Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.
Feasibility trial success could mean a new therapy, but not for a few years yet.
Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
The data are positive, but might not do much for the company’s sales.
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.